[{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CT-388","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Petrelintide","moa":"Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Petrelintide

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          April 24, 2025

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 (petrelintide) is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed for the treatment of obesity.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 17, 2025

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : The two companies will collaborate to co-develop and co-commercialise ZP8396 (petrelintide) in combination with CT-388 for the treatment of obesity.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : $1,650.0 million

                          March 12, 2025

                          Lead Product(s) : Petrelintide,CT-388

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : IND Enabling

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : $5,300.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          December 10, 2024

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 (petrelintide) is an potent long-acting amylin analogue designed to improve solubility, minimize fibrillation, holdin a potential for the treatment of overweight.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          June 20, 2024

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 28, 2023

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          FCE Pharma
                          Not Confirmed
                          FCE Pharma
                          Not Confirmed

                          Details : ZP8396 is an investigational, potent long-acting amylin analogue designed to improve solubility, minimize fibrillation and allow for co-formulation with other peptides, including GLP-1 analogues, it holds potential for the treatment of obesity.

                          Product Name : ZP8396

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 07, 2023

                          Lead Product(s) : Petrelintide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank